Innovent Biologics stock

1801 · HKEX · HKD

Compare Innovent Biologics
$85.80Change from previous close: +2.26%Absolute change: +$1.90

Close · November 17, 2026

Price history

−6.17% over the period

1 year: from $90.80 (November 17, 2025) to $85.20 (November 17, 2026), −6.17%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$85.20
October 30, 2026$79.75
September 30, 2026$98.05
August 31, 2026$103.80
July 31, 2026$86.70
June 30, 2026$79.60
May 29, 2026$83.35
April 30, 2026$90.00
March 31, 2026$84.90
February 27, 2026$85.10
January 30, 2026$81.10
December 31, 2025$76.25
November 28, 2025$94.10
November 17, 2025$90.80

At a glance

  • The company

    Biopharmaceutical company discovering and developing monoclonal antibodies and protein medicines for oncology, ophthalmology, autoimmune, cardiovascular and metabolic diseases

  • Latest results

    Quarter to June 30, 2025 · EPS ¥0.49 (estimate ¥0.26)

TickerLandia's take on Innovent Biologics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$69.55
52-wk high$112.70

−23.87% from the 52-week high

Analysts · 29 analysts

Average target$130.22+51.77% vs. price

Buy 27 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: Innovent Biologics

Compared with similar companies: high growth and high price.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Innovent Biologics is pricier than similar companies

Innovent Biologics's P/E (trailing 12 months): 111.5, +179% against the median of a group of 8 similar companies (40.0).

Compared with 8 similar companies

Innovent Biologics's metrics compared with similar companies
MetricInnovent BiologicsPosition in the groupBand
P/E (trailing 12 months)111.5High
Forward P/E33.6Middle
Operating margin7.4%Low
ROE7.0%Middle
Debt/equity0.11Middle

Grey band: the middle half of the group; tick: the median; dot: Innovent Biologics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥8.62B

Latest quarter · Q2 2026

Net income

¥1.25B

Latest quarter · Q2 2026

Quarterly net margin

14.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$147.79B
P/E
111.5
EPS
$0.76
Volume
6.7M
Daily trading
€108.43M
Dividend yield
0.00%

How Innovent Biologics is changing

All results
  • Revenue grew 27.7% a year on average over the last 5 years

  • Operating margin rose from −68.5% to 5.6%

  • Shares outstanding up 28.3% in 5 years

Returns

Innovent Biologics returns

$1,000 invested in Innovent Biologics 5 years ago, on November 17, 2021, would be worth $1,066 today: +6.57% in total, +1.28% per year. This is the price return only: dividends are excluded.

PeriodInnovent BiologicsHang Seng$1,000 becomes
1 month−2.52%−1.51%$975
6 months+4.63%−8.51%$1,046
Year to date+11.74%−8.28%$1,117
1 year−6.17%−10.90%$938
3 years+90.82%+34.68%$1,908
5 years+6.57%−8.35%$1,066

Over the last 6 months it has done better than 49% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Innovent Biologics: technical analysis

Innovent Biologics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 21.9% below its all-time closing high ($109.80, August 26, 2026).

Trend
No clear trend
RSI (14 sessions)
48
Between 30 and 70
vs 200-session average
−2.28%

Support and resistance

Price areas where Innovent Biologics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$99.61+16.10%4 touches, last on October 6, 2026
  2. Resistance$93.60+9.09%8 touches, last on August 17, 2026
  3. Resistance$90.77+5.80%2 touches, last on November 5, 2026
  4. Last price$85.80
  5. Support$84.70−1.28%4 touches, last on August 3, 2026
  6. Support$78.17−8.89%2 touches, last on November 2, 2026
  7. Support$75.97−11.46%5 touches, last on May 28, 2026

Volatility and risk

Over the last year it has moved more than the Hang Seng.

Beta (1 year) vs Hang Seng
1.32
Volatility (60 sessions, annualised)
45.1%
Largest fall in the last year
−27.73%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Innovent Biologics: seasonality

Average monthly price change over 8 years

−4.2%Jan+11.0%Feb−1.9%Mar+4.3%Apr+1.5%May+11.6%Jun+2.0%Jul+2.5%Aug+2.1%Sep−4.3%Oct+7.9%Nov+2.6%Dec

Over the last 8 years, the strongest month for Innovent Biologics has been June: +11.61% on average, positive in 5 years out of 8. The weakest has been October: −4.33% on average, positive in 2 years out of 8. November, the current month, has been positive in 5 years out of 8 (+7.92% on average).

Show chart data
MonthAverageMedianPositive years
January−4.24%−1.93%4 of 8
February+11.02%+12.45%6 of 8
March−1.93%−4.53%2 of 8
April+4.32%+6.28%6 of 8
May+1.47%−2.59%3 of 8
June+11.61%+7.28%5 of 8
July+1.99%+0.59%4 of 8
August+2.48%+1.79%6 of 8
September+2.12%+4.25%4 of 8
October−4.33%−5.88%2 of 8
November+7.92%+9.21%5 of 8
December+2.62%−3.95%3 of 8

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Innovent Biologics and its competitors

TYVYT, BYVASDA, SULINNO and Cyramza are among the brands through which Innovent Biologics, Inc. is best known, alongside Retsevmo and Jaypirca. The company works on antibody and protein medicines and takes them from discovery through manufacturing to sale, with therapies aimed at cancer, eye diseases, autoimmune conditions, heart disease and metabolic disorders. Besides its own portfolio, it distributes pharmaceutical products and provides consulting and research and development services. Its activity spans mainland China, the United States and Europe, as well as other international markets.

Headquarters
Suzhou, China
Employees
8,754
Founded
2011
Chief executive
De-Chao Yu
Innovent Biologics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Innovent Biologics1801$18.84B7.4%111.5+4.63%
WuXi Biologics (Cayman)2269$24.52B32.4%35.1+37.47%
Sichuan Kelun-Biotech Biopharmaceutical6990$13.65B-0.2%—−0.50%
Sino Biopharmaceutical1177$12.49B28.2%36.7+1.30%
Pharmaron Beijing300759$11.45B14.0%42.4+53.82%
Haisco Pharmaceutical Group002653$9.93B21.1%48.8+2.51%

Same industry or related industries, similar size. Compare Innovent Biologics with its competitors · Full profile